Editing Peripheral neuropathy (section)

=== Alternative medicine ===
A 2019 Cochrane review of the treatment of [[Herbalism|herbal medicinal]] products for people with neuropathic pain for at least three months concluded that "There was insufficient evidence to determine whether [[nutmeg]] or [[Hypericum perforatum|St John's wort]] has any meaningful efficacy in neuropathic pain conditions. The quality of the current evidence raises serious uncertainties about the estimates of effect observed, therefore, we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect."<ref>{{cite journal | vauthors = Boyd A, Bleakley C, Hurley DA, Gill C, Hannon-Fletcher M, Bell P, McDonough S | title = Herbal medicinal products or preparations for neuropathic pain | journal = The Cochrane Database of Systematic Reviews | volume = 4 | pages = CD010528 | date = April 2019 | issue = 5 | pmid = 30938843 | pmc = 6445324 | doi = 10.1002/14651858.CD010528.pub4 }}</ref>

A 2017 Cochrane review on the usage of [[acupuncture]] as a treatment for neuropathic pain concludes, "Due to the limited data available, there is insufficient evidence to support or refute the use of acupuncture for neuropathic pain in general, or for any specific neuropathic pain condition when compared with sham acupuncture or other active therapies." Also, "Most studies included a small sample size (fewer than 50 participants per treatment arm) and all studies were at high risk of bias for blinding of participants and personnel." Also, the authors state, "we did not identify any study comparing acupuncture with treatment as usual."<ref>{{cite journal | vauthors = Ju ZY, Wang K, Cui HS, Yao Y, Liu SM, Zhou J, Chen TY, Xia J | title = Acupuncture for neuropathic pain in adults | journal = The Cochrane Database of Systematic Reviews | volume = 12 | pages = CD012057 | date = December 2017 | issue = 7 | pmid = 29197180 | pmc = 6486266 | doi = 10.1002/14651858.CD012057.pub2 }}</ref>

Alpha [[lipoic acid]] (ALA) with benfotiamine is a proposed pathogenic treatment for painful diabetic neuropathy only.<ref>{{Cite web|url=http://www.currentdiabetesreviews.com/articles/170231/review-of-diabetic-polyneuropathy-pathogenesis-diagnosis-and-management-according-to-the-consensus-of-egyptian-experts|title = Review of Diabetic Polyneuropathy: Pathogenesis, Diagnosis A}}</ref> The results of two systematic reviews state that oral ALA produced no clinically significant benefit, intravenous ALA administered over three weeks may improve symptoms and that long-term treatment has not been investigated.<ref>{{Cite journal|last1=Bartkoski|first1=Scott|last2=Day|first2=Margaret|date=2016-05-01|title=Alpha-Lipoic Acid for Treatment of Diabetic Peripheral Neuropathy|journal=American Family Physician|volume=93|issue=9|pages=786|issn=1532-0650|pmid=27175957}}</ref>